Annual Statements Open main menu

ABEONA THERAPEUTICS INC. - Quarter Report: 2018 March (Form 10-Q)

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

(Mark One)

 

þ   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2018

Or

 

¨   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                          to                             

 

Commission file number 001-15771

 

ABEONA THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

 

Delaware

83-0221517 

(State or other jurisdiction of   (I.R.S. Employer I.D. No.)
incorporation or organization)    

 

1330 Avenue of the Americas, 33rd Floor, New York, NY 10019

(Address of principal executive offices)

 

(646) 813-4705

(Registrant’s telephone number, including area code)

 

3333 Lee Parkway, Suite 600, Dallas, TX 75219

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  þ  No  ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes þ   No  ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ¨   Accelerated filer þ
     
Non-accelerated filer ¨
(Do not check if a smaller reporting company)
  Smaller reporting company ¨
    Emerging growth company ¨

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging Growth Company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨ No þ

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

The number of shares outstanding of the registrant’s common stock as of May 10, 2018 was 47,305,285 shares.

 

 

 

 

 

 

ABEONA THERAPEUTICS INC.

 

INDEX

 

      Page No.
PART I - FINANCIAL INFORMATION  
       
   Item 1. Financial Statements:  
       
    Condensed Consolidated Balance Sheets at March 31, 2018 (unaudited) and December 31, 2017 14
       
    Condensed Consolidated Statements of Operations (unaudited) for the three months ended March 31, 2018 and March 31, 2017 15
       
    Condensed Consolidated Statement of Stockholders’ Equity (unaudited) for the three months ended March 31, 2018 16
       
    Condensed Consolidated Statements of Cash Flows (unaudited) for the three months ended March 31, 2018 and March 31, 2017 17
       
    Notes to Unaudited Condensed Consolidated Financial Statements 18
       
  Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 3
       
  Item 3. Quantitative and Qualitative Disclosures About Market Risk 11
       
  Item 4. Controls and Procedures 11
       
PART II - OTHER INFORMATION  
       
  Item 1. Legal Proceedings 12
       
  Item 1A. Risk Factors 12
       
  Item 6. Exhibits 12
       
SIGNATURES 13

 

 1 

 

 

PART I –FINANCIAL INFORMATION

 

This Quarterly Report on Form 10-Q (including the information incorporated by reference) contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. These statements and other risks described below as well as those discussed elsewhere in this Quarterly Report on Form 10-Q, documents incorporated by reference and other documents and reports that we file periodically with the Securities and Exchange Commission (“SEC”) include, without limitation, statements relating to uncertainties associated with research and development activities, clinical trials, our ability to raise capital, future cash flow, the future success of our marketed products and products in development, our sales projections and the sales projections of our licensing partners, anticipated product launches and our commercialization strategies, the terms of future licensing arrangements, our ability to secure additional financing for our operations, our ability to establish new relationships and maintain current relationships, our expectation that we will continue to incur losses, our belief that we will expend substantial funds to conduct research and development programs, preclinical studies and clinical trials of potential products, our belief that we have a rich pipeline of products and product candidates, our ability to achieve profitability on a sustained basis or at all, our expected cash burn rate, our belief that emerging insights in genetics and advances in biotechnology, as well as new approaches and collaboration between researchers, industry, regulators and patient groups, provide significant opportunities to develop breakthrough treatments for rare diseases, and our belief that the data from the expansion cohort of our Phase 1/2 clinical trial in ABO-102 (AAV-SGSH) for MPS IIIA, together with the data generated in the program to date, will allow us to submit a BLA. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “could,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of such terms or other comparable terminology. We intend the forward-looking statements to be covered by the safe harbor for forward-looking statements in these sections. The forward-looking information is based on various factors and was derived using numerous assumptions.

 

Forward-looking statements necessarily involve risks and uncertainties, and our actual results could differ materially from those anticipated in the forward-looking statements due to a number of factors. The forward-looking statements contained in this Quarterly Report on Form 10-Q represent our judgment only as of the date of this report. We caution readers not to place undue reliance on such statements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

 

ITEM 1.FINANCIAL STATEMENTS

 

The response to this Item is submitted as a separate section of this report. See page 14.

 

 2 

 

 

ITEM 2.MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

OVERVIEW

 

Abeona Therapeutics Inc. (together with our subsidiaries, “we,” “our,” “Abeona” or the “Company”) is a Delaware corporation. We are a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Our lead programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). We are also developing ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition we are developing a proprietary vector platform, AIM™, for next generation product candidates. Our principal executive office is located at 1330 Avenue of the Americas, 33rd Floor, New York, New York 10019. Our website address is www.abeonatherapeutics.com.

 

Recent Developments

 

On April 23, 2018, we announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to ABO-102, our AAV-mediated gene therapy for the treatment of Sanfilippo syndrome Type A (MPS IIIA).

 

On April 20, 2018, we announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted Orphan Drug designation (EMA/OD/013/18) for our gene therapy program ABO-202 for the treatment of subjects with neuronal ceroid lipofuscinosis, also known as Batten Disease, a fatal lysosomal storage disease that primarily affects the nervous system in children.

 

On March 29, 2018, F. Carsten Thiel Ph.D. was appointed by our Board of Directors as Chief Executive Officer. Timothy J. Miller, Ph.D. will remain President and assume the position of Chief Scientific Officer in charge of our clinical and preclinical research programs.

 

On March 15, 2018, we announced that the FDA has granted Rare Pediatric Disease Designation for the ABO-202 program (AAV-CLN1), our AAV-based gene therapy for the treatment of CLN1 disease (infantile and late infantile onset Batten disease).

 

On February 12, 2018, we announced that the FDA granted Orphan Drug Designation (ODD) to our ABO-202 program (AAV-CLN1), our AAV-based gene therapy for the treatment of infantile Batten disease.

 

ABO-202, developed with Steven Gray, Ph.D. and the support of The Saoirse Foundation, Taylor's Tale, Garrett the Grand Batten Fighter, Hayden's Batten Disease Foundation, and the Batten Disease Support and Research Association, is anticipated to enter clinical trials in 2018.

 

The preclinical data for ABO-202 were presented at the WORLDSymposium for Lysosomal Diseases held in San Diego, California from February 5-9, 2018. Key findings included:

 

·CLN1 mice recapitulate the major features of the human disease manifestations;
·A single intrathecal (IT) injection of self-complementary adeno-associated virus 9 (scAAV9) encoding the human CLN1 gene to CLN1 mice at 1 week and 1 month (pre-symptomatic) significantly increased their survival, improved behavior and reduced motor deficits;

 

 3 

 

 

·Higher IT doses further improved these observations, suggesting that methods increasing CNS exposure may be beneficial and provided some survival and behavioral benefit to symptomatic INCL mice; and
·A combination approach delivering ABO-202 by both intravenous and intrathecal routes of administration further increased survival efficacy 50% and improved potential treatment options for older animals with advanced disease manifestations.

 

On February 8, 2018, we announced updated clinical data from the ongoing Phase 1/2 trial for ABO-102 (AAV-SGSH), the Company’s investigational gene therapy for the treatment of Sanfilippo syndrome Type A (MPS IIIA), a rare autosomal-recessive lysosomal storage disease. The results demonstrate robust and durable clinical effects achieved throughout various time points post-administration. To date, 10 patients have been dosed with a single intravenous injection of ABO-102. Results were reported during the WORLDSymposium.

 

In the trial, subjects received a single intravenous injection of ABO-102 to facilitate systemic delivery of a corrective copy of the gene associated with onset and progression of MPS IIIA. Subjects were evaluated at multiple time points post-injection for safety assessments and signals of biopotency and clinical activity.

 

On February 7, 2018, we reported preliminary 30-Day safety and biopotency signals from the first patient dosed in the Company’s ongoing Phase 1/2 trial for ABO-101, a gene therapy treatment for patients with MPS IIIB (Sanfilippo syndrome Type B), enrolling at Nationwide Children’s Hospital in Columbus, Ohio. The ABO-101 therapy involves a single intravenous injection of AAV gene therapy for subjects with MPS IIIB, a rare autosomal recessive disease causing neurocognitive decline, speech and mobility loss, and premature death. Abeona plans to enroll a total of three patients in Cohort 1 (2E13 vg/kg) before dose-escalating to the Cohort 2 dose (5E13 vg/kg).

 

The Phase 1/2 study is designed to evaluate safety and preliminary indications of efficacy of ABO-101 in subjects suffering from MPS IIIB. In the first patient treated in Cohort 1:

 

·ABO-101, at a systemic dose of 2E13 vg/kg, is well-tolerated, with no treatment related adverse events or serious adverse events (SAEs) through 30 days of follow up;
·Early biopotency signals include significant heparan sulfate (HS) reductions observed in cerebral spinal fluid (50%), urine (69%), plasma (60%) and urinary total glycosaminoglycan (GAG) (67%);
·50% decline in CSF heparan sulfate from baseline supports previous AAV9 clinical observations that ABO-101 crossed the blood brain barrier after intravenous administration; and
·Normalized NAGLU enzyme activity observed represented by a greater than 300-fold increase over baseline at 30 days post administration.

 

Subjects in the Phase 1/2 trial receive a single, intravenous injection of ABO-101, which uses an AAV vector to introduce a corrective copy of the NAGLU gene associated with MPS IIIB disease. Subjects will be evaluated at multiple time points over the initial 30 days post-injection for safety assessments and initial signals of biopotency. Results in the first patient dosed with ABO-101 suggest strong CNS and broader systemic distribution, with the potential to reduce levels of glycosaminoglycans (GAGs) that represent the lysosomal storage pathology central to MPS IIIB disease progression.

 

 4 

 

 

On January 29, 2018, we announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to EB-101, the Company’s gene-corrected autologous cell therapy product for patients with recessive dystrophic epidermolysis bullosa (RDEB).

 

Product Development Strategy

 

Abeona is focused on developing and delivering gene therapy products for severe and life-threatening rare diseases. A rare disease is one that affects fewer than 200,000 people in the U.S. There are nearly 7,000 rare diseases, which may involve chronic illness, disability, and often, premature death. More than 25 million Americans and 30 million Europeans have a severe, life-threating disease. While rare diseases can affect any age group, about 50% of people affected are children (15 million) and rare diseases account for 35% of deaths in the first year of life. These rare diseases are often poorly diagnosed, very complex, and have no treatment or not very effective treatment. Over 95% of rare diseases do not have a single FDA or EMA approved drug treatment, however, most rare diseases are often caused by changes in genes. Approximately 80% of rare diseases are genetic in origin and can present at any stage of life. We believe emerging insights in genetics and advances in biotechnology, as well as new approaches and collaboration between researchers, industry, regulators and patient groups, provide significant opportunities to develop breakthrough treatments for rare diseases.

 

Developing Next Generation Gene Therapy

 

Gene therapy is the use of DNA as a potential therapy to treat a disease. In many disorders, particularly genetic diseases caused by a single genetic defect, gene therapy aims to treat a disease by delivering the correct copy of DNA into a patient’s cells. The healthy, functional copy of the therapeutic gene then helps the cell function correctly. In gene therapy, DNA that encodes a therapeutic protein is packaged within a ‘‘vector,’’ often a ‘‘naked’’ virus, which is used to transfer the DNA to the inside of cells within the body. Gene therapy can be delivered by a direct injection, either intravenously (IV) or directly into a specific tissue in the body, where it is taken up by individual cells. Once inside cells, the correct DNA is expressed by the cell machinery, resulting in the production of missing or defective protein, which in turn is used to treat the patient’s underlying disease and can provide long-term benefit.

 

Abeona is developing next-generation AAV gene therapies. Viruses such as AAV are utilized because they have evolved a way of encapsulating and delivering one or more genes of the size needed for clinical application, and can be purified in large quantities at high concentration. Unlike AAV vectors found in nature, the AAV vectors used by Abeona have been genetically-modified such that they do not replicate. Although the preclinical studies in animal models of disease demonstrate the promising impact of AAV-mediated gene expression to affected tissues such as the heart, liver and muscle, our programs use a specific virus that is capable of delivering therapeutic DNA across the blood brain barrier and into the central nervous system (CNS) and the somatic system (body), making them attractive for addressing lysosomal storage diseases which have severe CNS manifestations of the disease.

 

 5 

 

 

Lysosomal storage diseases (LSDs) are a group of rare inborn errors of metabolism resulting from deficiency in normal lysosomal function. These diseases are characterized by progressive accumulation of storage material within the lysosomes of affected cells, ultimately leading to cellular dysfunction. Multiple tissues ranging from musculoskeletal and visceral to tissues of the CNS are typically involved in disease pathology. Since the advent of enzyme replacement therapy (ERT) to manage some LSDs, general clinical outcomes have significantly improved; however, treatment with infused protein is lifelong and continued disease progression is still evident in patients. Thus, AAV-based gene therapy may provide a viable alternative or adjunctive therapy to current management strategies for LSDs.

 

Our initial programs are focused on LSDs such as Mucopolysaccharidosis (MPS) III A and IIIB. MPSIII, also known as Sanfilippo syndromes type A and type B, is a progressive neuromuscular disease with profound CNS involvement. Our lead product candidates, ABO-101 and ABO-102, have been developed to replace the damaged, malfunctioning enzymes within target cells with the normal, functioning version. ABO-201 is a similar product, using an AAV to deliver the correct lysosomal gene that is defective in juvenile neuronal ceroid lipofuscinosis. Delivered via a single injection, these drugs are only given once to a patient.

 

EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa and EB-201 for the Correction of Gene Mutations in Skin Cells (Keratinocytes)

 

EB-101 (LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES)), is an ex vivo gene therapy for the treatment of RDEB. EB-201 (AAVDJ-Col7A1) is a pre-clinical candidate targeting a novel, AAV-mediated gene editing and delivery approach to correct gene mutations in skin cells for patients with RDEB. We entered into an agreement (the ‘‘EB Agreement’’) with EB Research Partnership (‘‘EBRP’’) and Epidermolysis Bullosa Medical Research Foundation (‘‘EBMRF’’) to collaborate on gene therapy treatments for EB.

 

We entered into a license with Stanford effective August 3, 2016 for the EB-101 (LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES)) technology, and we have performed certain preclinical development work and are performing clinical trials of a gene therapy treatment for EB based upon such in-licensed technology.

 

We also entered into a license with Stanford effective August 3, 2016 for the EB-201 (AAV DJ COL7A1) technology, and we plan to perform preclinical development and clinical trials of a gene therapy treatment for EB based upon such in-licensed technology.

 

ABO-101 for MPS III B and ABO-102 for MPS III A (Sanfilippo syndrome)

 

MPS III (Sanfilippo syndrome) is a group of four inherited genetic diseases, described as type A, B, C or D, which cause enzyme deficiencies that result in the abnormal accumulation of glycosaminoglycans (sugars) in body tissues. MPS III is a lysosomal storage disease, a group of rare inborn errors of metabolism resulting from deficiency in normal lysosomal function. The incidence of MPS III (all four types combined) is estimated to be 1 in 70,000 births.

 

Mucopolysaccharides are long chains of sugar molecules used in the building of connective tissues in the body. There is a continuous process in the body of replacing used materials and breaking them down for disposal. Children with MPS III are missing an enzyme which is essential in breaking down used mucopolysaccharides. The partially broken down mucopolysaccharides remain stored in cells in the body causing progressive damage. Babies may show little sign of the disease, but as more and more cells become damaged, symptoms start to appear.

 

 6 

 

 

In MPS III, the predominant symptoms occur due to accumulation within the CNS, including the brain and spinal cord, resulting in cognitive decline, motor dysfunction, and eventual death. To date, there is no cure for MPS III and treatments are largely supportive.

 

Abeona is developing next-generation AAV-based gene therapies for MPS III, which involves a one-time delivery of a normal copy of the defective gene to cells of the CNS with the aim of reversing the effects of the genetic errors that cause the disease.

 

After a single dose in MPS III preclinical models, ABO-101 and ABO-102 induced cells in the CNS and peripheral organs to produce the missing enzymes which helped repair the damage caused to the cells. Preclinical in vivo efficacy studies in MPS III have demonstrated functional benefits that remain for months after treatment. A single dose of ABO-101 or ABO-102 significantly restored normal cell and organ function, corrected cognitive defects that remained months after drug administration, increased neuromuscular control and increased the lifespan of animals with MPS III over 100% one year after treatment compared to untreated control animals. These results are consistent with studies from several laboratories suggesting AAV treatment could potentially benefit patients with MPS III A and B. In addition, safety studies conducted in animal models of MPS III have demonstrated that delivery of ABO-101 or ABO-102 are well tolerated with minimal side effects.

 

ABO-201 for juvenile Batten disease (or Juvenile Neuronal Ceroid Lipofuscinoses) (JNCL) and ABO-202 (AAV-CLN1) gene therapy for treatment of infantile Batten disease (or Infantile Neuronal Ceroid Lipofuscinoses) (INCL)

 

ABO-201 (AAV CLN3) is an AAV-based gene therapy which has shown promising preclinical efficacy in delivery of a normal copy of the defective CLN3 gene to cells of the CNS with the aim of reversing the effects of the genetic errors that cause JNCL. JNCL is a rare, fatal, autosomal recessive (inherited) disorder of the nervous system that typically begins in children between 4 and 8 years of age. Often the first noticeable sign of JNCL is vision impairment, which tends to progress rapidly and eventually result in blindness. As the disease progresses, children experience loss of previously acquired skills (developmental regression). This regression usually begins with the loss of the ability to speak in complete sentences. Children then lose motor skills, such as the ability to walk or sit. They also develop movement abnormalities that include rigidity or stiffness, slow or diminished movements (hypokinesia), and stooped posture. Beginning in mid- to late childhood, affected children may have recurrent seizures (epilepsy), heart problems, behavioral problems, and difficulty sleeping. Life expectancy is greatly reduced. Most people with juvenile Batten disease live into their twenties or thirties. As yet, no specific treatment is known that can halt or reverse the symptoms of JNCL.

 

JNCL is the most common form of a group of disorders known as neuronal ceroid lipofuscinoses (NCLs). Collectively, all forms of NCL affect an estimated 2 to 4 in 100,000 live births in the United States. NCLs are more common in Finland, where approximately 1 in 12,500 individuals are affected, as well as Sweden, other parts of northern Europe, and Newfoundland, Canada.

 

 7 

 

 

Most cases of JNCL are caused by mutations in the CLN3 gene, which is the focus of our AAV-based gene therapy approach. These mutations disrupt the function of cellular structures called lysosomes. Lysosomes are compartments in the cell that normally digest and recycle different types of molecules. Lysosome malfunction leads to a buildup of fatty substances called lipopigments and proteins within these cell structures. These accumulations occur in cells throughout the body, but neurons in the brain seem to be particularly vulnerable to damage. The progressive death of cells, especially in the brain, leads to vision loss, seizures, and intellectual decline in children with JNCL.

 

ABO-202 (AAV9 CLN1) is an AAV-based gene therapy which has shown promising preclinical efficacy in delivery of a normal copy of the defective CLN1 gene to cells of the central nervous system with the aim of reversing the effects of the genetic errors that cause an infantile form of Batten disease (also known as infantile neuronal ceroid lipofuscinosis).

 

ABO-301 for Fanconi Anemia (FA) and ABO-302 for rare blood diseases using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases

 

ABO-301 (AAV-FANCC) is an AAV-based gene therapy which has shown promising preclinical efficacy in delivery of a normal copy of the defective gene to cells of the hematopoietic or blood system with the aim of reversing the effects of the genetic errors that cause FA. FA is a rare (1 in 160,000) pediatric, autosomal recessive (inherited) disease characterized by multiple physical abnormalities, organ defects, bone marrow failure, and a higher than normal risk of cancer. The average lifespan for people with FA is 20 to 30 years.

 

The major function of bone marrow is to produce new blood cells. In FA, a DNA mutation renders the FANCC gene nonfunctional. Loss of FANCC causes skeletal abnormalities and leads to bone marrow failure. FA patients also have much higher rates of hematological diseases, such as acute myeloid leukemia or tumors of the head, neck, skin, gastrointestinal system, or genital tract. The likelihood of developing one of these cancers in people with FA is between 10 and 30 percent. Aside from bone marrow transplantation, there are no specific treatments known that can halt or reverse the symptoms of FA. Repairing fibroblast cells in FA patients with a functional FANCC gene is the focus of our AAV-based gene therapy approach.

 

Using a novel CRISPR (clustered, regularly interspaced short palindromic repeats)-Cas9 (CRISPR associated protein 9) system, researchers used a protein-RNA complex composed of an enzyme known as Cas9 bound to a guide RNA molecule that has been designed to recognize a particular DNA sequence. The RNA molecules guide the Cas9 complex to the location in the genome that requires repair. CRISPR-Cas9 uniquely enables surgically efficient knock-out, knock-down or selective editing of defective genes in the context of their natural promoters, unlocking the potential to treat both recessive and dominant forms of genetic diseases. Most importantly, this approach has the potential to allow for more precise gene modification.

 

Polymer Hydrogel Technology (PHT™)

 

MuGard® (mucoadhesive oral wound rinse) approved for mucositis, stomatitis, aphthous ulcers, and traumatic ulcers

 

MuGard is our marketed product for the management of oral mucositis, a frequent side-effect of cancer therapy for which there is no other established treatment. MuGard, a proprietary nanopolymer formulation, received marketing clearance from the FDA in the U.S. as well as Europe, China, Australia, New Zealand and Korea. We launched MuGard in the U.S. in 2010 and licensed MuGard for commercialization in the U.S. to AMAG Pharmaceuticals, Inc. (AMAG) in 2013. We licensed MuGard to RHEI Pharmaceuticals, N.V. for China and other Southeast Asian countries in 2010; Hanmi Pharmaceutical Co. Ltd. for South Korea in 2014; and Norgine B.V. for the European Union, Switzerland, Norway, Iceland, Lichtenstein, Australia and New Zealand in 2014.

 

 8 

 

 

LIQUIDITY AND CAPITAL RESOURCES

 

We have historically funded our operations primarily through public and private sales of common stock, preferred stock, convertible notes and through licensing agreements. Our principal source of liquidity is cash and cash equivalents. Licensing payments and royalty revenues provided limited funding for operations during the period ended March 31, 2018. As of March 31, 2018, our cash and cash equivalents were $131,995,000.

 

As of March 31, 2018, our working capital was $127,697,000. Our working capital at March 31, 2018 represented a decrease of $7,288,000 as compared to our working capital of $134,985,000 as of December 31, 2017. The decrease in working capital at March 31, 2018 reflects three months of net operating costs and changes in current assets and liabilities offset by proceeds from exercise of stock options and warrants.

 

On October 16, 2017, we announced a collaborative agreement between nine Sanfilippo foundations to provide up to approximately $13.85 million of grants to Abeona in installments for the advancement of the Company’s clinical stage gene therapies for Sanfilippo Syndrome Type A (MPS IIIA) and Sanfilippo Syndrome Type B (MPS IIIB), subject to the achievement of certain milestones. As of March 31, 2018, we received $3.1 million in grants ($2.6 million in the fourth quarter 2017 and $0.5 million in the first quarter of 2018) and recorded them as deferred revenue. $2.6 million of the $3.1 million in grants were recorded as revenues in the first quarter of 2018.

 

If we raise additional funds by selling additional equity securities, the relative equity ownership of our existing investors will be diluted and the new investors could obtain terms more favorable than previous investors.

 

We have incurred negative cash flows from operations since inception, and have expended, and expect to continue to expend in the future, substantial funds to complete our planned product development efforts. Since inception, our expenses have significantly exceeded revenues, resulting in an accumulated deficit as of March 31, 2018 of $364,592,000. We cannot provide assurance that we will ever be able to generate sufficient product sales or royalty revenue to achieve profitability on a sustained basis, or at all.

 

Since our inception, we have devoted our resources primarily to fund our research and development programs. We have been unprofitable since inception and to date have received limited revenues from the sale of products. We expect to incur losses for the next several years as we continue to invest in product research and development, preclinical studies, clinical trials and regulatory compliance.

 

FIRST QUARTER 2018 COMPARED TO FIRST QUARTER 2017

 

Our licensing revenue for the first quarter of 2017 was $151,000. In 2017, we recognized licensing revenue over the period of the performance obligation under our licensing agreements under ASC 605, Revenue Recognition. Effective January 1, 2018, we adopted Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers, as amended (commonly referred to as ASC 606) using the modified retrospective transition method. The cumulative effect of applying the standard was an increase of $3.7 million to stockholders’ equity as of January 1, 2018. There was no licensing revenue for the first quarter of 2018 due to ASC 606.

 

 9 

 

 

We recorded revenue for Foundation Grants of $2,548,000 for first quarter of 2018 and no revenues for the same period of 2017, an increase of $2,548,000. We recorded revenue to match expenses for the advancement of the Company’s clinical stage gene therapies for Sanfilippo Syndrome Type A (MPS IIIA) and Sanfilippo Syndrome Type B (MPS IIIB).

 

We recorded royalty revenue for MuGard of $50,000 for first quarter of 2018 and $35,000 for the same period of 2017, an increase of $15,000. We licensed MuGard to AMAG and Norgine and receive quarterly royalties under our agreements.

 

Total research and development spending for the first quarter of 2018 was $8,162,000, as compared to $2,198,000 for the same period of 2017, an increase of $5,964,000. The increase in expenses was primarily due to:

 

·increased clinical and development work for the manufactured product for EB-101, ABO-102, ABO-101 and other gene therapy products ($4,307,000);
·increased salary and related costs ($633,000) from the hiring of scientific staff;
·increased stock option compensation expense ($488,000); and
·other net increases in research spending ($536,000).

 

Total general and administrative expenses were $2,878,000 for the first quarter of 2018, as compared to $3,022,000 for the same period of 2017, a decrease of $144,000. The decrease in expenses was due primarily to:

 

·decreased restricted common stock based compensation expense ($188,000)
·decreased stock option compensation expense ($80,000); and
·offset by increases in net other general and administrative expenses ($124,000).

 

Depreciation and amortization was $174,000 for the first quarter of 2018 as compared to $250,000 for the same period in 2017, a decrease of $76,000. We are amortizing the licenses for ABO-101 and ABO-201, and EB-102 over the life of the patents. The decrease is due to lower amortization of licensed technology ($116,000) offset by an increase in depreciation ($40,000). SDF Alpha was amortized through May 26, 2017. The license was returned to the licensor, Plasma Technologies, LLC in 2017.

 

Total operating expenses for the first quarter of 2018 were $11,214,000 as compared to total operating expenses of $5,470,000 for the same period of 2017, an increase of $5,744,000 for the reasons listed above.

 

Interest and miscellaneous income was $156,000 for the first quarter of 2018 as compared to $39,000 for the same period of 2017, an increase of $117,000. Most of the increase was due to increased interest income due to higher cash balances ($109,000) and other miscellaneous income ($8,000).

 

Interest and other expense for the first quarter of 2018 was $3,000 as compared to $2,000 for the same period of 2017.

 

 10 

 

 

Net loss for the first quarter of 2018 was $8,463,000, or a $0.18 basic and diluted loss per common share as compared to a net loss of $5,247,000, or a $0.13 basic and diluted loss per common share, for the same period in 2017, an increased loss of $3,216,000.

 

OFF-BALANCE SHEET ARRANGEMENTS

 

We did not have any off - balance sheet arrangements as of March 31, 2018.

 

ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We are exposed to a variety of financial risks in the normal course of our business, including market risk (including currency and price risk), credit risk and liquidity risk. Our overall risk management program focuses on preservation of capital and the unpredictability of financial markets and has sought to minimize potential adverse effects on our financial performance and position.

 

Market Risk

 

Currency risk

We are exposed to foreign exchange risk arising from various currencies, primarily with respect to the U.S. dollar and to a lesser extent to the euro, Australian dollar and British pound. As our U.S. operating entity primarily conducts its operations in U.S. dollars, its exposure to changes in foreign currency is insignificant.

 

Price risk

The market prices for the provision of preclinical and clinical materials and services, as well as external contracted research, may vary over time.

 

The commercial prices of any of our products or product candidates are currently uncertain.

 

We are not exposed to commodity price risk.

 

We do not hold investments classified as available-for-sale or at fair value through profit or loss; therefore, we are not exposed to equity securities price risk.

 

Credit Risk

 

Credit risk is managed on a consolidated basis. Credit risk arises from cash and cash equivalents and deposits with banks and financial institutions, outstanding receivables and committed transactions with collaboration partners and security deposits paid to landlords. We currently have no wholesale debtors.

 

We deposited funds as security to our landlords related to our facility in Cleveland, Ohio and our facility in Dallas, Texas.

 

Our cash and cash equivalents include bank balances, demand deposits and other short-term highly liquid investments (with maturities of less than three months at the time of purchase) that are readily convertible into a known amount of cash and are subject to an insignificant risk of fluctuation in value. Restricted cash includes deposits made in relation to facility leases. Cash, cash equivalents and restricted cash were placed at Comerica Bank.

 

Liquidity Risk

 

We believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months. We manage liquidity through a rolling forecast of our liquidity reserve on the basis of expected cash flow and raise cash if and when needed through the issuance of shares.

 

ITEM 4.CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Under the supervision and with the participation of our management and consultants, including the Executive Chairman (our principal executive officer) and Vice President Finance (our principal accounting officer), we have conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (“Disclosure Controls and Procedures”), as such term is defined in Exchange Act Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of March 31, 2018.

 

Conclusion of Evaluation — Based on this Disclosure Controls and Procedures evaluation, the Executive Chairman and Chief Accounting Officer concluded that our Disclosure Controls and Procedures as of March 31, 2018 were effective.

 

Changes In Internal Control Over Financial Reporting – During the three months ended March 31, 2018, we implemented appropriate changes to our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) to support the recognition of revenue and the preparation of additional revenue-related disclosures in accordance with ASC 606.

 

 11 

 

 

PART II -- OTHER INFORMATION

 

ITEM 1.LEGAL PROCEEDINGS.

 

We are not currently subject to any material legal proceedings.

 

ITEM 1A.RISK FACTORS.

 

As of the date of this filing, there have been no material changes to the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2017, as filed with the SEC on March 16, 2018.

 

ITEM 6.EXHIBITS.

 

Exhibits:  
   
10.1+ Employment Agreement dated March 29, 2018 between the Company and F. Carsten Thiel
   
31.1 Principal Executive Officer Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
   
31.2 Principal Financial Officer Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
   
32.1* Principal Executive Officer Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
   
32.2* Principal Financial Officer Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
101 The following materials from Abeona’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, formatted in XBRL (Extensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets at March 31, 2018 and December 31, 2017, (ii) Condensed Consolidated Statements of Operations for the three months ended March 31, 2018 and March 31, 2017, (iii) Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2018, (iv) Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2018 and March 31, 2017, and (v) Notes to Condensed Consolidated Financial Statements, tagged as blocks of text.

 

 

*This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of the Section, nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language in any filing.

 

+Management contract or compensatory plan required to be filed as an Exhibit to this Form pursuant to Item 15c of the report.
 12 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  

  ABEONA THERAPEUTICS INC.
     
Date: May 10, 2018 By: /s/ Steven H. Rouhandeh
    Steven H. Rouhandeh
    Executive Chairman
    (Principal Executive Officer)
     
Date: May 10, 2018 By: /s/ Stephen B. Thompson
    Stephen B. Thompson
    Sr. Vice President Finance
    (Principal Financial & Accounting Officer)

 

 13 

 

 

Abeona Therapeutics Inc. and Subsidiaries

 

Condensed Consolidated Balance Sheets

 

   March 31, 2018   December 31, 2017 
   (unaudited)     
ASSETS          
           
Current assets          
Cash and cash equivalents  $131,995,000   $137,750,000 
Receivables   64,000    107,000 
Prepaid expenses and other current assets   2,092,000    2,735,000 
Total current assets   134,151,000    140,592,000 
Property and equipment, net   4,789,000    1,374,000 
Licensed technology, net   3,890,000    3,977,000 
Goodwill   32,466,000    32,466,000 
Other assets and restricted cash   357,000    357,000 
Total assets  $175,653,000   $178,766,000 
           
LIABILITIES AND STOCKHOLDERS' EQUITY          
           
Current liabilities          
Accounts payable  $5,910,000   $2,393,000 
Current portion of deferred revenue   544,000    3,214,000 
Total current liabilities   6,454,000    5,607,000 
           
Deferred revenue, net of current portion   -    3,061,000 
Total liabilities   6,454,000    8,668,000 
Commitments and contingencies          
Stockholders' equity          
Common stock - $.01 par value; authorized 200,000,000 shares; issued, 47,232,940 at March 31, 2018 and 46,888,108 at December 31, 2017   472,000    469,000 
Additional paid-in capital   533,319,000    529,421,000 
Accumulated deficit   (364,592,000)   (359,792,000)
Total stockholders' equity   169,199,000    170,098,000 
Total liabilities and stockholders' equity  $175,653,000   $178,766,000 

 

The accompanying notes are an integral part of these condensed consolidated statements.

 

 14 

 

 

Abeona Therapeutics Inc. and Subsidiaries

 

Condensed Consolidated Statements of Operations

(unaudited)

 

   Three Months ended March 31, 
   2018   2017 
Revenues          
Foundation grants  $2,548,000   $- 
Royalties   50,000    35,000 
License revenues   -    151,000 
Total revenues   2,598,000    186,000 
           
Expenses          
Research and development   8,162,000    2,198,000 
General and administrative   2,878,000    3,022,000 
Depreciation and amortization   174,000    250,000 
Total expenses   11,214,000    5,470,000 
Loss from operations   (8,616,000)   (5,284,000)
           
Interest and miscellaneous income   156,000    39,000 
Interest and other expense   (3,000)   (2,000)
    153,000    37,000 
Net loss  $(8,463,000)  $(5,247,000)
           
Basic and diluted loss per common share  $(0.18)  $(0.13)
           
Weighted average number of common shares outstanding   47,060,523    40,254,679 

 

The accompanying notes are an integral part of these condensed consolidated statements.

 

 15 

 

 

Abeona Therapeutics Inc. and Subsidiaries

 

Condensed Consolidated Statements of Stockholders' Equity

(unaudited)

 

   Common Stock             
   Shares   Amount  

Additional

paid-in

capital

   Accumulated
deficit
  

Total

stockholders’

equity

 
Balance, December 31, 2017 – as reported   46,888,108   $469,000   $529,421,000   $(359,792,000)  $170,098,000 
Cumulative effect adjustment of ASC 606 on January 1, 2018   -    -    -    3,663,000    3,663,000 
Stock based compensation expense   -    -    1,900,000    -    1,900,000 
Vesting of restricted common stock issued to employees   -    -    172,000    -    172,000 
Common stock issued for cash exercise of options   267,196    3,000    1,682,000    -    1,685,000 
Exercise of $5.00 warrants   28,874    -    144,000    -    144,000 
Cashless warrant exercises   48,762    -    -    -    - 
Net loss   -    -    -    (8,463,000)   (8,463,000)
Balance, March 31, 2018   47,232,940   $472,000   $533,319,000   $(364,592,000)  $169,199,000 

 

The accompanying notes are an integral part of these condensed consolidated statements.

 

 16 

 

 

Abeona Therapeutics Inc. and Subsidiaries

 

Condensed Consolidated Statements of Cash Flows

(unaudited)

 

   Three Months ended March 31, 
   2018   2017 
Cash flows from operating activities:          
Net loss  $(8,463,000)  $(5,247,000)
Adjustments to reconcile net loss to cash used
in operating activities:
          
Depreciation and amortization   174,000    250,000 
Stock option compensation expense   1,900,000    1,492,000 
Restricted common stock issued to directors and employees   172,000    362,000 
Change in operating assets and liabilities:          
Receivables   43,000    (24,000)
Prepaid expenses and other current assets   643,000    (308,000)
Accounts payable and accrued expenses   3,517,000    (2,231,000)
Deferred revenue   (2,068,000)   (151,000)
Net cash used in operating activities   (4,082,000)   (5,857,000)
           
Cash flows from investing activities:          
Capital expenditures   (3,502,000)   (74,000)
Net cash used in investing activities   (3,502,000)   (74,000)
           
Cash flows from financing activities:          
Proceeds from exercise of stock options   1,685,000    - 
Proceeds from exercise of $5.00 warrants   144,000    1,000 
Net cash provided by financing activities   1,829,000    1,000 
           
Net decrease in cash, cash equivalents and restricted cash   (5,755,000)   (5,930,000)
Cash, cash equivalents and restricted cash at beginning of period   138,030,000    69,142,000 
Cash, cash equivalents and restricted cash at end of period  $132,275,000   $63,212,000 
           
Supplemental cash flow disclosures:          
Cash and cash equivalents  $131,995,000   $63,212,000 
Restricted cash   280,000    - 
Total cash, cash equivalents and restricted cash  $132,275,000   $63,212,000 
           
Cash paid for interest  $3,000   $2,000 

 

The accompanying notes are an integral part of these condensed consolidated statements.

 

 17 

 

 

Abeona Therapeutics Inc. and Subsidiaries

 

Notes to Condensed Consolidated Financial Statements

Three Months Ended March 31, 2018 and 2017

(unaudited)

 

Abeona Therapeutics Inc. (together with our subsidiaries, “we,” “our,” “Abeona” or the “Company”) is a Delaware corporation. We are a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Our lead programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). We are also developing ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition we are developing a proprietary vector platform, AIM™, for next generation product candidates. Our efforts have been principally devoted to research and development, resulting in significant losses.

 

(1)Interim Financial Statements

 

The condensed consolidated balance sheet as of March 31, 2018, the condensed consolidated statements of operations for the three months ended March 31, 2018 and 2017, the condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2018, and the condensed consolidated statements of cash flows for the three months ended March 31, 2018 and 2017, were prepared by management without audit. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, except as otherwise disclosed, necessary for the fair presentation of the financial position, results of operations, and changes in financial position for such periods, have been made.

 

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these interim financial statements be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2017. The results of operations for the period ended March 31, 2018 are not necessarily indicative of the operating results which may be expected for a full year. The condensed consolidated balance sheet as of December 31, 2017 contains financial information taken from the audited Abeona consolidated financial statements as of that date.

 

As of March 31, 2018, we had 5,807,531 options and 2,838,576 warrants that were not included in the EPS calculation as their effect would be antidilutive.

 

 18 

 

 

(2)New Accounting Standards Implemented

 

Revenue Recognition

Effective January 1, 2018, we adopted Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers, as amended (commonly referred to as ASC 606) using the modified retrospective transition method. The cumulative effect of applying the standard was an increase of $3.7 million to stockholder’s equity as of January 1, 2018. Our statement of operations for the quarterly period ended March 31, 2018 and our balance sheet as of March 31, 2018 are presented under ASC 606, while our statement of operations for the quarterly period ended March 31, 2017 and our balance sheet as of December 31, 2017 are presented under ASC 605, Revenue Recognition. See below for disclosure of the impact of the adoption of ASC 606 on our statement of operations and balance sheet for the quarterly period ended March 31, 2018, and the effect of changes made to our consolidated balance sheet as of January 1, 2018.

 

The table below presents the cumulative effect of the changes made to the consolidated January 1, 2018 balance sheet due to the adoption of ASC 606.

 

   December 31, 2017,      January 1, 2018 
Balance Sheet  As Reported Under   Adjustments Due   As Adjusted 
(in thousands)  ASC 605   to ASC 606   Under ASC 606 
             
Liabilities               
Current liabilities               
Current portion of deferred revenue  $3,214   $(602)  $2,612 
Total current liabilities   3,214    (602)   2,612 
Deferred revenue, net of current portion   3,061    (3,061)   - 
Total liabilities   8,668    (3,663)   5,005 
Stockholders’ Equity               
Accumulated deficit   (359,792)   3,663    (356,129)
Total equity  $170,098   $-   $170,098 

 

The table below presents the impact of the adoption of ASC 606 on our statement of operations.

 

   First Quarter Ended March 31, 2018 
STATEMENT OF OPERATIONS  Under   Effect of   As Reported 
(in thousands except per share amounts)  ASC 605   ASC 606   Under ASC 606 
Revenues               
License revenues  $151   $(151)  $- 
Total revenues BS   2,749    (151)   2,598 
                
Loss from operations  $(8,465)  $(151)  $(8,616)
Net loss  $(8,312)  $(151)  $(8,463)
                
Basic and diluted loss per common share  $(0.18)  $0.00   $(0.18)

 

 19 

 

 

The table below presents the impact of the adoption of ASC 606 on our balance sheet.

 

   March 31, 2018 
Balance Sheet  Under   Effect of   As Reported 
(in thousands)  ASC 605   ASC 606   Under ASC 606 
Liabilities and Stockholders’ Equity               
Current liabilities               
Current portion of deferred revenue  $1,146   $(602)  $544 
Total current liabilities   7,056    (602)   6,454 
Deferred revenue, net of current portion   2,910    (2,910)   - 
Total liabilities   9,966    (3,512)   6,454 
                
Stockholders’ Equity               
Accumulated deficit   (368,255)   (3,663)   (364,592)
Total stockholders’ equity  $165,536   $3,663   $169,199 

 

We received upfront cash payments for licenses of our technology in years 2008-2014. The revenue was recognized straight-line over the life of the patent. Our obligation was performed at the time the license was granted. Following the revenue recognition policies in accordance with ASC 606, we decreased the accumulated deficit by $3,663,000 as of January 1, 2018 and decreased deferred revenue by the same amount.

 

Royalty revenues will continue to be recognized in the period of sales. Royalties recognized in the first quarter of 2018 are $50,000.

 

On October 16, 2017, we announced a collaborative agreement between nine Sanfilippo foundations to provide up to approximately $13.85 million of grants to Abeona in installments for the advancement of the Company’s clinical stage gene therapies for Sanfilippo Syndrome Type A (MPS IIIA) and Sanfilippo Syndrome Type B (MPS IIIB), subject to the achievement of certain milestones. As of March 31, 2018, we received $3.1 million in grants ($2.6 million in the fourth quarter 2017 and $0.5 million in the first quarter of 2018) and recorded them as deferred revenue. $2.6 million of the $3.1 million in grants were recognized as revenue in the first quarter of 2018. Deferred revenue was $544,000 at March 31, 2018.

 

We recorded revenue for Foundation Grants of $2,548,000 for first quarter of 2018 and no revenues for the same period of 2017, an increase of $2,548,000. We record revenue to match expenses for the advancement of the Company’s clinical stage gene therapies for Sanfilippo Syndrome Type A (MPS IIIA) and Sanfilippo Syndrome Type B (MPS IIIB).

 

We recorded revenue for Foundation Grants of $2,548,000 for first quarter of 2018 and no revenues for the same period of 2017, an increase of $2,548,000. We record revenue to match expenses for the advancement of the Company’s clinical stage gene therapies for Sanfilippo Syndrome Type A (MPS IIIA) and Sanfilippo Syndrome Type B (MPS IIIB).

 

Restricted cash disclosure

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows, Restricted Cash requiring restricted cash and restricted cash equivalents to be included with cash and cash equivalents on the statement of cash flows when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The guidance is effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted. We adopted this standard during the first quarter of 2018. Restricted cash is now included as a component of cash, cash equivalents, and restricted cash on our unaudited condensed consolidated statements of cash flows. Restricted cash is recorded within other non-current assets in the accompanying unaudited condensed consolidated balance sheets. The inclusion of restricted cash increased beginning balances of the unaudited condensed consolidated statements of cash flows by $280,000 and $0, respectively, and the ending balances by $280,000 and $0, respectively, for the three months ended March 31, 2018 and 2017.

 

(3)Licensed Technology

 

On May 15, 2015, we acquired Abeona Therapeutics LLC which had a an exclusive license through Nationwide Children’s Hospital to the AB-101 and AB-102 patent portfolios for developing treatments for patients with Sanfilippo Syndrome Type A and Type B. The license is amortized over the life of the license of 20 years.

 

On August 3, 2016, we announced we entered into an agreement (the “EB Agreement”) with EB Research Partnership (“EBRP”) and Epidermolysis Bullosa Medical Research Foundation (“EBMRF”) to collaborate on gene therapy treatments for EB.

 

We also entered into a license with Stanford for the AAV-based gene therapy EB-201 (AAV DJ COL7A1) technology, and we shall perform preclinical development and perform clinical trials of a gene therapy treatment for EB based upon such in-licensed technology. EB-201 (AAV DJ COL7A1) is a pre-clinical candidate targeting a novel, AAV-mediated gene editing and delivery approach (known as homologous recombination) to correct gene mutations in skin cells (keratinocytes) for patients with recessive dystrophic epidermolysis bullosa (RDEB). The licenses are amortized over the life of the license of 20 years.

 

 20 

 

 

Licensed technology consists of the following:

 

   March 31,   December 31, 
   2018   2017 
Licensed technology  $4,608,000   $4,608,000 
Less accumulated amortization   718,000    631,000 
Licensed technology, net  $3,890,000   $3,977,000 

 

Intangible assets consist of the following (in thousands):

 

   March 31, 2018   December 31, 2017 
  

Gross

carrying

value

  

 

Accumulated

amortization

  

Gross

carrying

value

  

 

Accumulated

Amortization

 
Amortizable intangible assets                    
Licensed technology  $4,608   $718   $4,608   $631 

 

Amortization expense related to intangible assets totaled $87,000 for the three months ended March 31, 2018 and totaled $203,000 for the three ended March 31, 2017. The aggregate estimated amortization expense for intangible assets remaining as of March 31, 2018 is as follows (in thousands):

 

 

2018  $259 
2019   346 
2020   346 
2021   346 
2022   346 
over 5 years   2,247 
      
Total  $3,890 

 

(4)Fair Value Measurements

 

We calculate the fair value of our assets and liabilities which qualify as financial instruments and include additional information in the notes to the consolidated financial statements when the fair value is different than the carrying value of these financial instruments. The estimated fair value of receivables, prepaids and other and accounts payable approximate their carrying amounts due to the relatively short maturity of these instruments.

 

U.S. GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. This guidance establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

 

·Level 1 – Quoted prices in active markets for identical assets or liabilities.
·Level 2 – Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

 

 21 

 

 

·Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs.

 

The guidance requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

 

We have segregated all financial assets and liabilities that are measured at fair value on a recurring basis (at least annually) into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below.

 

Financial assets and liabilities measured at fair value on a non-recurring and recurring basis as of March 31, 2018 and December 31, 2017 are summarized below:

 

(in thousands)                    
   As of                 
   March 31,               Total Gains 
Description  2018   Level 1   Level 2   Level 3   (Losses) 
Non-recurring                         
Assets:                         
Licensed technology (net)  $3,890   $-   $-   $3,890   $87 
Goodwill   32,466    -    -    32,466    - 

 

(in thousands)                    
   As of                 
   December 31,               Total Gains 
Description  2017   Level 1   Level 2   Level 3   (Losses) 
Non-recurring                         
Assets:                         
Licensed technology (net)  $3,977   $-   $-   $3,977   $127 
Goodwill   32,466    -    -    32,466    - 
Recurring                         
Liabilities:                         
Contingent  consideration  $-   $-   $-   $-   $1,391 

 

(5)Stock Based Option Compensation and Restricted Stock Compensation

 

For the three months ended March 31, 2018, we recognized stock-based compensation expense of $1,900,000 for granted options. For the three months ended March 31, 2017, we recognized stock-based compensation expense of $1,492,000.

 

 22 

 

 

The following table summarizes stock-based compensation for the three months ended March 31, 2018 and 2017:

 

   Three months ended 
   March 31, 
   2018   2017 
Research and development  $1,056,000   $356,000 
General and administrative   844,000    1,136,000 
Stock-based compensation expense  included in operating expense  $1,900,000   $1,492,000 

 

For the three months ended March 31, 2018, we granted 645,000 stock options and for the three months ended March 31, 2017, we granted no stock options.

 

For the three months ended March 31, 2018, the fair value of options was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions: dividend yield of 0%; volatility of 1.09%; risk-free interest rate of 2.37%; and expected lives of 5.0 years. The weighted average fair value of options granted was $10.83 per share. The weighted average grant date fair value is $10.83 and the weighted average exercise price is $13.72.

 

For the three months ended March 31, 2018, we recognized restricted common stock compensation expense of $172,000 for granted restricted common stock. For the three months ended March 31, 2017, we recognized restricted stock compensation expense of $362,000 for granted restricted common stock compensation expense.

 

The following table summarizes restricted common stock compensation expense for the three months ended March 31, 2018 and 2017:

 

   Three months ended 
   March 31, 
   2018   2017 
Research and development  $-   $- 
General and administrative   172,000    362,000 
Stock-based compensation expense  included in operating expense  $172,000   $362,000 

 

For the three months ended March 31, 2018 and 2017, no stock was granted.

 

(6)Commitments and Contingencies

 

We are not currently subject to any material pending legal proceeding.

 

At March 31, 2018, we had construction in-progress to build out manufacturing facilities at our Cleveland location. We had a remaining construction commitment of $1,456,000 at March 31, 2018.

 

 23